Long-term Results of Intravitreal Anti-VEGF Injections in Wet AMD: A Meta-Analysis

Klinische Monatsblatter fur Augenheilkunde

Volumn 233, Issue 4, 2016, Pages 471-474

  Gerding, Heinrich ^a,b  

^a Augenzentrum Klinik Pallas   (Switzerland)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

aflibercept; age related macular degeneration; AMD; anti VEGF; bevacizumab; macula; meta analysis; nAMD; ranibizumab; retina; review; wAMD

Indexed keywords

VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR;

AGE RELATED MACULAR DEGENERATION; FOLLOW UP; HUMAN; META ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; VISUAL ACUITY; AGED; CAUSALITY; COMORBIDITY; DRUG EFFECTS; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; MALE; PREVALENCE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TUNISIA; VISION DISORDERS; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; CAUSALITY; COMORBIDITY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; LONGITUDINAL STUDIES; MALE; PREVALENCE; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME; TUNISIA; VISION DISORDERS; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84966716397     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0041-111835     Document Type: Review

References (19)

1. Peden M. C., Suner I. J., Hammer M. E. et al. Fixed-interval dosing of anit-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology: 2015; 122 803 808
2. Lala C., Framme C., Wolf-Schnurrbusch U. EK et al. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exsudative age-related macular degeneration. Acta Ophthalmologica: 2013; 91 526 530
3. Beykin G., Grunin M., Averbukh E. et al. Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome. BMC Ophthalmology: 2015; 15 39
4. Borooah S., Jeganathan V. S., Ambrecht A. M. et al. Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland. Eye (Lond): 2015; 29 1156 1161
5. Gillies M. C., Campain A., Barthelmes D. et al. Long-term outcomes of treatment of neovascular age-related macular degeneration. Ophthalmology: 2015; 122 1837 1845
6. Buckle M., Donachie P. HJ, Johnston R. L. Long-term outcomes of intravitreal ranibizumab for neovascular are-related macular degeneration in a well defined region of the UK. Br J Ophthalmol: 2016; 100 240 245
7. Frennesson C. I., Nilsson S. EG. A three-year follow-up of ranibizumab treatment of exsudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outs. Acta Ophthalmologica: 2014; 92 216 220
8. Pushpoth S., Sykakis E., Merchant K. et al. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol: 2012; 96 1469 1473
9. Rasmussen A., Bloch S. B., Fuchs J. et al. A 4-year longitutinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology: 2013; 120 2630 2636
10. Zhu M., Chew J. K., Broadhead G. K. et al. Intravitreal ranibizumab for neovascular age-related macular degeneration in clinical practice: five-year treatment outcome. Graefes Arch Clin Exp Ophthalmol: 2015; 253 1217 1225
11. Mrejen S., Jung J. J., Chen C. et al. Long-term visual outcome for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration. J Clin Med: 2015; 4 1380 1402
12. Rofagha S., Bhisitkul R. B., Boyer D. S. et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON. A multicenter cohort study (SEVEN-UP). Ophthalmology: 2013; 120 2292 2299
13. Silva R., Axer-Siegel R., Eldem B. et al. The SECURE Study. Long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology: 2013; 120 130 139
14. Amstutz C. A., Fleischhauer J., Zweifel S. et al. Langzeit-Verlauf bei Patienten mit intravitrealer anti-VEGF Therapie für neovaskuläre AMD. Klin Monatsbl Augenheilkd: 2015; 232 533 537
15. Boulanger-Scemama E., Querques G., About F. et al. Ranibizumab for exsudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting. J Fr Ophthalmol: 2015; 38 620 627
16. Shah A. R., Del Priore L. V. Natural history of predominantely classic, minimally classic, and occult subgroups in exsudative age-related macular degeneration. Ophthalmology: 2009; 116 1901 1907
17. Gerding H. Treatment of wet AMD with less than 12 injections of ranibizumab per year. Klin Monbl Augenheilk: 2010; 227 294 297
18. Gerding H., Loukopoulos V., Riese J. et al. Results of flexible ranibizumab in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol: 2011; 249 653 662
19. Gerding H. Ranibizumab treatment in age-related macular degeneration: a meta-analysis of one-year results. Klin Monbl Augenheilk: 2014; 231 427 431